Arcutis Biotherapeutics, Inc.
News
Los Angeles Capital Management LLC Has $1.26 Million Stock Position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)
Zolmax Los Angeles Capital Management LLC lowered its stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 8.4% during the second quarter, according to the company in its most recent Form...\n more…
Zurcher Kantonalbank Zurich Cantonalbank Takes Position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)
Ticker Report Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) in the second quarter, Holdings Channel.com reports. The fund acquired...\n more…
Candriam S.C.A. Makes New $12.16 Million Investment in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)
Ticker Report Candriam S.C.A. bought a new position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor...\n more…
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire WESTLAKE VILLAGE, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations...\n more…
Arcutis Completes Enrollment of Phase 1b Alopecia Areata Study Evaluating ARQ-255
Globe Newswire ARQ-255 is a topical Janus kinase 1 (JAK1) inhibitor suspension formulated as a potential topical treatment for alopecia areataProprietary Deep Dermal Drug Delivery (4D) technology formulated to...\n more…